CAPTRUST Financial Advisors
ADAP

CAPTRUST Financial Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-68,723
Closed -$8.93K – 2736
2025
Q3 		$8.93K Sell
68,723
-10,360
-13% -$1.42K ﹤0.01% 2617
2025
Q2 		$19K Sell
79,083
-1,526
-2% -$407 ﹤0.01% 2471
2025
Q1 		$15.9K Sell
80,609
-1,020
-1% -$528 ﹤0.01% 2325
2024
Q4 		$44K Sell
81,629
-1,412
-2% -$1.03K ﹤0.01% 2247
2024
Q3 		$78.9K Hold
83,041
– – ﹤0.01% 2214
2024
Q2 		$81K Sell
83,041
-28,911
-26% -$31.7K ﹤0.01% 2125
2024
Q1 		$177K Buy
111,952
+94,698
+549% +$114K ﹤0.01% 2009
2023
Q4 		$13.7K Sell
17,254
-4,670
-21% -$2.63K ﹤0.01% 2630
2023
Q3 		$17.1K Hold
21,924
– – ﹤0.01% 2527
2023
Q2 		$20.3K Buy
21,924
+302
+1% +$360 ﹤0.01% 2461
2023
Q1 		$23.6K Buy
+21,622
New +$33.5K ﹤0.01% 2243
2022
Q4 		– Sell
-19,622
Closed -$21K – 2054
2022
Q3 		$21K Buy
19,622
+15,000
+325% +$27.6K ﹤0.01% 2015
2022
Q2 		$8K Hold
4,622
– – ﹤0.01% 3853
2022
Q1 		$10K Buy
4,622
+3,682
+392% +$9.94K ﹤0.01% 3786
2021
Q4 		$4K Hold
940
– – ﹤0.01% 4153
2021
Q3 		$5K Hold
940
– – ﹤0.01% 3926
2021
Q2 		$4K Hold
940
– – ﹤0.01% 3924
2021
Q1 		$5K Buy
+940
New +$5.38K ﹤0.01% 3707

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

CAPTRUST Financial Advisors's ADAP Position: Q4 2025 in Review

CAPTRUST Financial Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 68,723 shares — an estimated $8.93K sold.

CAPTRUST Financial Advisors first reported a position in ADAP in Q1 2021 and held it in 18 quarters. The position peaked at $177K in Q1 2024. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • CAPTRUST Financial Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 68,723 Adaptimmune Therapeutics shares in Q4 2025, an estimated $8.93K.
  • CAPTRUST Financial Advisors first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 18 quarters.
  • CAPTRUST Financial Advisors's Adaptimmune Therapeutics position peaked at $177K in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.